Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.47 |
| ▸ | EGFR | P00533 | 15/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482094 | 0.94 | BTK (0.58) | BTKERBB2EGFRERBB4JAK3 | |
| SCHEMBL6495527 | 0.84 | ERBB2 (0.52) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6483179 | 0.82 | ERBB2 (0.46) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6484248 | 0.82 | ERBB2 (0.50) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6482672 | 0.81 | ERBB2 (0.62) | BTKERBB2EGFRERBB4JAK3 | |
| SCHEMBL6492412 | 0.79 | ERBB2 (0.67) | BTKERBB2EGFRERBB4JAK3 | |
| SCHEMBL6493576 | 0.79 | BTK (0.58) | BTKEGFR | |
| SCHEMBL6482092 | 0.77 | ERBB2 (0.46) | ERBB2EGFRERBB4JAK3MEN1 | |
| SCHEMBL6484938 | 0.76 | ERBB2 (0.54) | BTKERBB2EGFRERBB4JAK3 | |
| SCHEMBL6482142 | 0.75 | ERBB2 (0.59) | ERBB2EGFRERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | BTK 204/4885ERBB2 440/4885EGFR 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.